Bavarian Nordic Repurchases Shares Under DKK 250M Buyback Plan
Danish biotech Bavarian Nordic discloses transactions under a share buyback program running through late October 2026.
Bavarian Nordic A/S, the Copenhagen-listed biopharmaceutical company trading on the Nasdaq Copenhagen exchange under the ticker BAVA, disclosed on October 5, 2026, transactions conducted as part of an ongoing share repurchase program that was launched September 1, 2026.
The program authorizes the company to buy back its own shares for a total value of up to DKK 250 million, with all repurchases to be completed no later than October 30, 2026. The relatively compressed two-month window signals that the company is moving with urgency to return capital to shareholders or manage dilution within a defined fiscal period.
Read more Plume Launches nBND Vault Tokenizing Fidelity Bond ETF Shares →
All transactions are being carried out in compliance with European Union market abuse regulations, specifically Regulation (EU) No. 596/2014 and Commission Delegated Regulation (EU) 2016/1052 — the framework collectively known as the Safe Harbour Regulation. Operating within Safe Harbour rules provides the company legal certainty that its buyback activity will not be treated as market manipulation under EU law, a standard practice among publicly listed European firms executing structured repurchase programs.
Bavarian Nordic has not disclosed the specific number of shares acquired in the latest tranche, the average purchase price, or the cumulative total repurchased since the program's inception, details that are typically released in weekly or periodic transaction summaries. Investors tracking the program's progress should monitor subsequent filings for updated figures on volume and pricing.
Continue reading at GlobeNewswire - Industry News on Financial Services.
